An Overview of Patients’ Quality of Life on Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors

Pharmacy Times interviewed Jonathan Strosberg, MD, a professor of medical oncology, section head of the Neuroendocrine Tumor Program, and vice president of Medical Oncology at the Moffitt Cancer Center, on his presentation at the 2021 American Society of Clinical Oncology Annual Meeting about the NETTER-1 phase 3 trial of lutetium Lu 177 dotatate (Lutathera, Novartis) for midgut neuroendocrine tumors.

During the discussion, Strosberg detailed patients reports of their quality of life while on lutetium Lu 177 dotatate for the treatment of advanced midgut neuroendocrine tumors during the phase 3 trial.